Table 1.
Baseline characteristics of patients.
| Variable | Overall (n = 90) | STEMI (n = 46) | NSTEMI (n = 44) | p-Value |
|---|---|---|---|---|
| Age, years | 67.2 ± 9.1 | 66.2 ± 8.8 | 68.2 ± 9.4 | 0.308 1 |
| Male sex | 71 (78.9%) | 35 (76.1%) | 36 (81.8%) | 0.505 1 |
| Body mass index, kg/m2 | 27.08 ± 2.54 | 27.45 ± 2.71 | 26.70 ± 2.31 | 0.158 3 |
| Waist-to-hip ratio | 1.04 ± 0.68 | 1.04 ± 0.68 | 1.04 ± 0.69 | 0.630 3 |
| Systolic blood pressure, mmHg | 134.7 ± 21.0 | 134.3 ± 21.3 | 135.1 ± 20.9 | 0.845 3 |
| Diastolic blood pressure, mmHg | 79.7 ± 12.6 | 81.2 ± 12.3 | 78.1 ± 12.9 | 0.252 3 |
| Heart rate at admission, bpm | 75.0 ± 16.9 | 76.7 ± 18.6 | 73.3 ± 14.9 | 0.353 3 |
| Diabetes mellitus | 13 (14.4%) | 4 (8.7%) | 9 (20.5%) | 0.140 2 |
| Arterial hypertension | 51 (56.7%) | 27 (58.7%) | 24 (54.5%) | 0.832 1 |
| Smoking | 43 (47.8%) | 24 (52.2%) | 19 (43.2%) | 0.393 1 |
| Dyslipidemia | 14 (15.6%) | 6 (13.0%) | 8 (18.2%) | 0.501 1 |
| Atrial fibrillation | 12 (13.3%) | 8 (17.4%) | 4 (9.1%) | 0.355 2 |
| Family history of cardiovascular disease | 17 (18.9%) | 10 (21.7%) | 7 (15.9%) | 0.480 1 |
| History of PCI or CABG | 16 (17.8%) | 4 (8.7%) | 12 (27.3%) | 0.028 2 |
| History of CV-related hospitalizations | 24 (26.7%) | 5 (10.9%) | 19 (43.2%) | 0.001 2 |
| GRACE score, points | 121.4 ± 22.0 | 121.1 ± 23.1 | 121.7 ± 23.1 | 0.906 3 |
| Left ventricular ejection fraction, % | 50.7 ± 10.3 | 51.2 ± 9.7 | 50.1 ± 11.1 | 0.652 3 |
| Mean Killip class * | 1.0 (1.0-1.0) | 1.0 (1.0-1.0) | 1.1 (1.0-1.0) | 0.136 4 |
| ST segment deviation in first contact ECG | 82 (91.1%) | 46 (100%) | 36 (81.8%) | 0.002 1 |
| PCI performed while in-hospital | 74 (82.2%) | 44 (95.7%) | 30 (68.2%) | 0.001 1 |
| Multi-vessel disease | 10 (13.3%) | 2 (4.4%) | 8 (26.7%) | 0.012 2 |
| Beta-blocker use | 29 (32.2%) | 12 (26.1%) | 17 (38.6%) | 0.203 1 |
| ACE inhibitor or ARB use | 41 (45.6%) | 21 (45.7%) | 20 (45.5%) | 0.985 1 |
| Calcium channel blocker use | 14 (15.6%) | 8 (17.4%) | 6 (13.6%) | 0.623 1 |
| Statin use | 18 (20.0%) | 6 (13.0%) | 12 (27.3%) | 0.092 1 |
| Diuretic use | 20 (22.2%) | 8 (17.4%) | 12 (27.3%) | 0.260 1 |
| Acetylsalicylic acid use | 23 (25.6%) | 7 (15.2%) | 16 (36.4%) | 0.021 1 |
| P2Y12 inhibitor use | 4 (4.4%) | 1 (2.2%) | 3 (6.8%) | 0.355 2 |
| Anticoagulant use | 7 (7.8%) | 4 (8.7%) | 3 (6.8%) | 1.000 2 |
| Prothrombin time—INR | 1.09 ± 0.39 | 1.07 ± 0.25 | 1.11 ± 0.50 | 0.608 3 |
| Activated partial thromboplastin time, s | 24.13 ± 4.02 | 23.96 ± 4.21 | 24.32 ± 3.85 | 0.672 3 |
| C-reactive protein, mg/L | 6.4 ± 5.0 | 6.6 ± 5.2 | 6.2 ± 4.9 | 0.664 3 |
| High-sensitivity cardiac troponin I at admission, ng/L | 331.0 ± 293.8 | 335.2 ± 306.1 | 326.9 ± 284.8 | 0.894 3 |
| Potassium, mmol/L | 4.04 ± 0.40 | 3.98 ± 0.39 | 4.10 ± 0.41 | 0.176 3 |
| Urea, mmol/L | 7.6 ± 3.2 | 7.0 ± 2.2 | 8.2 ± 4.0 | 0.094 3 |
| Creatinine, μmol/L | 0.428 | 88.0 ± 21.6 | 102.9 ± 44.3 | 0.045 3 |
Data are presented as mean ± standard deviation or n (%); * Data presented as median (interquartile range); 1 Chi-squared test; 2 Fisher’s exact test; 3 t-test for independent samples; 4 Mann–Whitney U test; WHO: World Health Organization; COPD: chronic obstructive pulmonary disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting, CV: cardiovascular; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; INR: international normalized ratio.